Publications by authors named "Jaffe G"
Purpose: To compare the development of macular atrophy (MA) in eyes treated with the Port Delivery System with ranibizumab (PDS) with those treated with monthly intravitreal ranibizumab injections in the Archway trial.
Design: Preplanned exploratory analysis of a phase 3, open-label, randomized trial.
Participants: Patients with neovascular age-related macular degeneration (nAMD) diagnosed within 9 months of screening, previously treated with and responsive to anti-vascular endothelial growth factor therapy.
Article Synopsis
- The study aims to evaluate how functional and structural assessments can serve as endpoints in clinical trials for retinal degeneration linked to USH2A mutations.
- Participants with specific visual capabilities underwent various eye tests over four years, focusing on understanding changes in their vision.
- Findings indicated that certain tests were more sensitive to detecting changes, influencing the design of future clinical trials related to this condition.
Since its founding, American Orthopsychiatric Association (AOA) has been at the forefront of working at the intersection of mental health and social justice. In (Shore & Mannino, 1975), former organization president and journal editor Milton Shore and Fortune Mannino wrote that the association had consistently held a philosophy that included (a) a commitment to an interdisciplinary approach in the study of mental health problems and the development of mental health programs; (b) an emphasis on prevention as well as treatment; (c) the integration of the clinical and the social; (d) a major focus on the social scene and its interweaving with mental health problems in individuals within society; and (e) an avoidance of dilettantism, superficiality, and well-meaning generalizations through a commitment to high-quality research, thoughtful analysis of mental health issues, and high professional standards of practice in all areas of mental health. (PsycInfo Database Record (c) 2024 APA, all rights reserved).
View Article and Find Full Text PDFPurpose: To report the safety and efficacy of brolucizumab (Beovu) 6 mg versus aflibercept (Eylea) 2 mg administered every 4 weeks in participants with neovascular age-related macular degeneration (nAMD) and persistent retinal fluid after the week 52 up to week 104.
Design: Multicenter, randomized, double-masked phase 3a study.
Participants: Participants with recalcitrant nAMD (persistent residual retinal fluid despite previous frequent anti-VEGF treatment).
Oxidative stress-mediated retinal pigment epithelial (RPE) cell damage is associated with age-related macular degeneration (AMD). ST266 is the biological secretome produced by a novel population of amnion-derived multipotent progenitor cells. Herein, we investigated the effect of ST266 on RPE cell injury induced by hydroquinone (HQ), a cigarette smoke related oxidant, hydrogen peroxide (HO) and all-trans retinal (atRal), a pro-oxidant component of the retinoid cycle.
View Article and Find Full Text PDFBackground: Underutilization of primary care and receipt of preventive health services have been reported among women with opioid use disorder. The aim of this study was to describe perceptions of primary care among women in treatment for opioid use disorder.
Methods: Between May and June 2022, 27 women who were receiving treatment for opioid use disorder from one opioid treatment program participated in this study.
Article Synopsis
- The study compared fundus autofluorescence (FAF) and optical coherence tomography (OCT) measurements of geographic atrophy (GA) to evaluate the effectiveness of avacincaptad pegol (ACP) treatment in a clinical trial called GATHER1.
- A post hoc analysis showed a strong correlation (r = 0.93) between FAF and OCT measurements, indicating that both methods provided similar results in assessing GA area.
- The OCT showed a significant reduction in GA growth between ACP and sham groups at 12 and 18 months, confirming that OCT can be a reliable method for measuring GA in clinical settings.
Background: Frequent anti-vascular endothelial growth factor A (VEGF-A) injections reduce the risk of rapid and severe vision loss in patients with neovascular age-related macular degeneration (nAMD); however, due to undertreatment, many patients lose vision over time. New treatments that provide sustained suppression of VEGF-A are needed. RGX-314 (currently known as ABBV-RGX-314) is an adeno-associated virus serotype 8 vector that expresses an anti-VEGF-A antigen-binding fragment, which provides potential for continuous VEGF-A suppression after a single subretinal injection.
View Article and Find Full Text PDFArticle Synopsis
- - The synopsis covers two studies, GATHER1 (2021) and GATHER2 (2023), focusing on the impact of avacincaptad pegol (ACP) on adult participants with geographic atrophy (GA), an advanced form of dry age-related macular degeneration.
- - Findings from both studies indicated that ACP can slow the progression of GA compared to a sham injection, with similar reading abilities maintained after one year of treatment.
- - While ACP shows promise as a potential treatment for GA, further research is necessary to determine its effectiveness and safety, and patients should consult their doctors before making any treatment decisions.
To analyze post-marketing cases of retinal vasculitis after intravitreal pegcetacoplan. The American Society of Retina Specialists (ASRS) Research and Safety in Therapeutics (ReST) Committee as well as an expert panel performed a retrospective review of cases of retinal vasculitis reported to the ASRS. Clinical and imaging characteristics were reviewed for evidence of retinal vasculitis and analyzed.
View Article and Find Full Text PDFPurpose: To evaluate the 2-year efficacy, durability, and safety of dual angiopoietin-2 and vascular endothelial growth factor (VEGF) A pathway inhibition with intravitreal faricimab according to a personalized treat-and-extend (T&E)-based regimen with up to every-16-week dosing in the YOSEMITE and RHINE (ClinicalTrials.gov identifiers, NCT03622580 and NCT03622593, respectively) phase 3 trials of diabetic macular edema (DME).
Design: Randomized, double-masked, noninferiority phase 3 trials.
Purpose: The LIGHTSITE III study evaluated multiwavelength photobiomodulation (PBM) therapy in nonexudative (dry) age-related macular degeneration (AMD) using the LumiThera Valeda Light Delivery System.
Methods: LIGHTSITE III is a randomized, controlled trial to assess the safety and effectiveness of PBM in dry AMD. Subjects were given multiwavelength PBM (590, 660, and 850 nm) or Sham treatment delivered in a series of nine sessions over 3 to 5 weeks every four months over 24 months.
Purpose: The aim of this analysis was to characterize the spectrum of inflammatory changes arising from brolucizumab use in routine clinical practice.
Design: Retrospective analysis of fluorescein angiography (FA), fundus photography (FP) and OCT images taken at the time of adverse event.
Subjects: Brolucizumab-treated patients with neovascular age-related macular degeneration with retinal vasculitis (RV) and/or retinal vascular occlusion (RO) reported to Novartis Patient Safety between February 2020 and January 2021.
Objective: To validate GATHER-1 inclusion criteria and the study's primary anatomic end point by assessing the reproducibility of geographic atrophy (GA) measurements and factors that affect reproducibility.
Design: Post hoc analysis of phase II/III clinical trial.
Subjects: All 286 participants included in the GATHER-1 study.
Purpose: To describe a case of bilateral panuveitis in an 11-year-old girl with autoimmune lymphoproliferative syndrome (ALPS) due to haploinsufficiency.
Case Description: A 5-year-old girl developed cervical adenopathy, and autoimmune hemolytic anemia and thrombocytopenia consistent with Evan's Syndrome. She was subsequently diagnosed with autosomal dominant haploinsuffciency and treated with immunosuppressants.
Article Synopsis
- Geographic atrophy is a severe type of dry age-related macular degeneration that can cause significant vision loss, and this study evaluates the safety and effectiveness of avacincaptad pegol 2 mg in slowing its progression.
- The GATHER2 trial was a comprehensive, double-masked, sham-controlled study conducted over 24 months, involving 448 participants aged 50 and older, divided into two groups receiving either the treatment or a sham injection.
- Results showed a significant reduction in the growth of geographic atrophy lesions in patients receiving avacincaptad pegol compared to those who received the sham treatment over 12 months.
Purpose: The purpose of this study was to report a case of Pseudomonas aeruginosa endophthalmitis after surgical 0.59 mg fluocinolone acetonide implant in a patient with a long-standing Crawford tube.
Methods: This was a retrospective case review.
Laser sails propelled by gigawatt-scale ground-based laser arrays have the potential to reach relativistic speeds, traversing the solar system in hours and reaching nearby stars in years. Here, we describe the danger interplanetary dust poses to the survival of a laser sail during its acceleration phase. We show through multiphysics simulations how localized heating from a single optically absorbing dust particle on the sail can initiate a thermal runaway process that rapidly spreads and destroys the entire sail.
View Article and Find Full Text PDFArticle Synopsis
- The HAWK and HARRIER studies focused on comparing the effectiveness and safety of brolucizumab and aflibercept for treating neovascular age-related macular degeneration in patients who had not been treated before.
- A post hoc analysis was conducted on pooled data to assess disease activity in eyes treated with brolucizumab versus aflibercept during the first year, specifically looking at various assessment weeks.
- Results showed that brolucizumab-treated eyes had a lower incidence of disease activity and less fluid compared to aflibercept, suggesting better fluid resolution and potential for extending treatment intervals in the first year.
Purpose: To determine the interreader agreement for reticular pseudodrusen (RPD) assessment on combined infrared reflectance (IR) and OCT imaging in the early stages of age-related macular degeneration across a range of different criteria to define their presence.
Design: Interreader agreement study.
Participants: Twelve readers from 6 reading centers.
Article Synopsis
- A 37-year-old woman with recurring eye inflammation after a fluocinolone acetonide implant exchange developed primary vitreoretinal lymphoma (PVRL), which initially presented as postoperative endophthalmitis.
- * She was previously treated with adalimumab for idiopathic bilateral panuveitis and experienced worsening symptoms despite treatment.
- * The case suggests a possible link between adalimumab therapy and the development of PVRL, highlighting the need for further investigation into this relationship.